Jagsonpal Pharmaceuticals: Buying Its Way Into Specialty Pharma, One Self-Funded Deal at a Time

A balance sheet built for M&A optionality - and a management team using it. From the Yash Pharma brand buy-in to the Aequitas Healthcare hospital-channel entry, JPL is compounding through disciplined, all-cash acquisitions rather than dilution or debt.

Before assessing whether Jagsonpal should be acquiring, it's worth establishing that it clearly can. Every acquisition discussed in this note - ₹92.5 Cr for Yash Pharma, ₹20.8 Cr for Aequitas - was funded entirely from internal accruals. No debt was raised and no shares were issued for either deal. That capacity did not appear overnight; it was built deliberately over FY22–FY26.

· Where the cash came from: working capital discipline

Net working capital days fell from 59 to 11 (working capital as a percentage of sales fell from 16.1% to 3.8%), freeing up cash that would otherwise sit in receivables and inventory. Free cash flow conversion (FCF/EBITDA) rose from 52% to 92% - JPL is now turning almost all of its accounting profit into distributable, deployable cash.

· Margin expansion did the rest

Revenue compounded at a modest 7.2% a year, but because gross margins expanded and overheads didn't scale proportionally, EBITDA compounded at 24.9% and operational PAT at 23.9% (2.4x over four years). Cash on the balance sheet is 4.1x its FY22 level, and free cash flow is 8x - the single most important number for a company that wants to keep acquiring without borrowing.

The Precedent - Yash Pharmaceuticals Limited

In May 2024, the company acquired Yash Pharma's India and Bhutan operations, including its brands and trademarks, for a total consideration of ₹924.7 million. The acquisition was strategically compelling for three reasons: (1) there was no overlap between Yash Pharma's portfolio and JPL's core therapeutic focus areas of gynaecology and orthopaedics, (2) it offered strong geographic complementarity, with Yash Pharma's presence in East and West India complementing JPL's traditionally strong North India franchise, and (3) it expanded the combined doctor reach by nearly 50%, taking the prescriber base to approximately 154,000 doctors.

More importantly, Jagsonpal demonstrated strong business integration capabilities by seamlessly integrating the acquired portfolio, laying the foundation for sustained growth and validating the strategic rationale behind the acquisition.

Aequitas Healthcare: buying the hospital channel JPL never had

Announced in stages between 29 June and 17 July 2026, this is Jagsonpal's most recent and strategically distinct acquisition.

What Jagsonpal actually bought?

Aequitas is a PAN-India hospital and institutional distribution platform: 4,400+ hospital relationships (Medanta, Max, Manipal, Cloudnine, Rainbow among the named accounts), 8,000+ doctor connections, and a 49-person field force, operating through two divisions - Hospital/Critical Care (injectables) and Generics/Fusion (non-injectables). Its own financials, however, tell a story of a small, flattish, thinly-profitable business:

The implied 100% equity value of ?24.5 Cr puts the deal at roughly 0.46x trailing sales - against JPL's own shares, which trade at roughly 5.0x sales. That gap is the point: management is betting it can lift Aequitas's EBITDA from ?0.5 Cr to a targeted ?10 Cr within two years of integration, mostly by cross-selling JPL's existing portfolio through Aequitas's hospital network and consolidating overheads and supply chain. If that target is hit, JPL will have paid roughly 2.4x forward EBITDA for a business that, once integrated, plausibly deserves something closer to JPL's own ~19–26x EV/EBITDA trading multiple - the kind of multiple arbitrage that, if it works, is worth many multiples of the ?20.8 Cr cheque.

On valuation: two acquisitions, two very different playbooks

Yash Pharma was priced as a profitable, established brand portfolio: at ~?47.7 Cr of FY24 revenue and an estimated ~12% EBITDA margin, the ?92.47 Cr consideration works out to roughly 1.94x EV/Sales and ~16x EV/EBITDA - a full, non-distressed multiple for cash-generative, no-overlap brands. Aequitas, by contrast, was bought at ~0.46x sales - optionality priced far below Yash Pharma's earnings-based multiple, because the earnings aren't there yet. Same balance sheet, same management team, two different pricing logics depending on what's actually being bought: cash flow versus access.

 

Summing up

Jagsonpal has built itself strong enough to acquire and expand on different verticals. The company has never owned a hospital-channel relationship before. Aequitas Healthcare gives it one instantly - 4,400+ institutional hospital relationships and 8,000+ doctor connections that management says would otherwise take 4–6 years to build organically - for a cash outlay (?20.8 Cr) that is less than half of one quarter's operating cash flow. That is the story this note is built around: a company using a strengthened balance sheet to buy time and access, not just brands.

Disclaimer - Informational only. Not investment advice.
GoIndia Advisors LLP | SEBI Registered Research Analyst | Reg. No. INH000020040 | BSE Enlistment No. - 6518